Effect of recombinant human interleukin 11 on recovery of platelets after peripheral blood hematopoietic stem cell transplantation.
- Author:
Jing-Dong LI
1
;
Xiao-Lin HAN
;
Sun WU
Author Information
1. Department of Hematology, The First Affiliated Hospital, Xinxiang Medical College, Weihui 453100, China. Ljd2004@126.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Blood Platelets;
drug effects;
Female;
Humans;
Interleukin-11;
therapeutic use;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
methods;
Platelet Count;
Recombinant Proteins;
therapeutic use;
Young Adult
- From:
Journal of Experimental Hematology
2009;17(1):226-228
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to explore the effect of recombinant human interleukin 11 (rhIL-11) on platelet recovery after peripheral blood hematopoietic stem cell transplantation and its side-effects. 20 patients with hematologic malignancies treated by allogeneic peripheral blood stem cell transplantation (PBSCT) were randomly divided into test and control groups. The patients in test group were treated with rhIL-11 since the day 6 after PBSCT, while the patients in control group were given supporting treatment. The results showed that the average time of the platelet to recover to 20 x 10(9)/L was 22.8 days in test group and 27.3 days in control group (p < 0.01). The average time for platelet to recover to 50 x 10(9)/L was 25.7 days in test group, and 32.3 days in control group (p < 0.01). The average number of megakaryocytes was 15.6 in test group, and 7.8 in control group on day 30 after PBSCT (p < 0.01). In conclusion, the rhIL-11 is able to accelerate platelet recovery after peripheral blood hematopoietic stem cell transplantation.
